Topical Treatment for HIV-Related Kaposi's Sarcoma
Name of the Trial
Why Is This Trial Important?
Laboratory studies have shown that halofuginone, an experimental drug, can block the growth and spread of certain cancer cells and can also block the flow of blood to tumors, a process called antiangiogenesis. Unlike other drugs used to treat Kaposi's sarcoma, which must be given by vein or by mouth, halofuginone may be effective when given as a cream or ointment and applied directly to tumors. This could result in fewer side effects."
In animal studies, halofuginone has been found to inhibit collagen production and angiogenesis, even if applied directly to tumors rather than given internally," said Dr. Krown. "With this trial, we are applying halofuginone to skin lesions of Kaposi's sarcoma to see if this treatment approach is effective and safe."
In this trial, people with Kaposi's sarcoma will have some of their skin tumors treated with an ointment containing halofuginone, while other tumors will be treated with an ointment that does not contain the drug. Several of the tumors will be biopsied to see if the halofuginone ointment affects tumors differently than the non-halofuginone ointment. After 12 weeks, if the halofuginone-treated tumors are improved or do not get worse, all of the skin tumors may be treated for another 12 weeks with halofuginone ointment.
Who Can Join This Trial?
Where Is This Trial Taking Place?
Who to Contact
An archive of "Featured Clinical Trial" columns is available at http://cancer.gov/clinicaltrials/ft-all-featured-trials.